The primary immunodeficiency disorders by Shields, Adrian & Patel, Smita Y
 
 
The primary immunodeficiency disorders
Shields, Adrian; Patel, Smita Y
DOI:
10.1016/j.mpmed.2017.07.011
License:
Creative Commons: Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)
Document Version
Peer reviewed version
Citation for published version (Harvard):
Shields, A & Patel, SY 2017, 'The primary immunodeficiency disorders', Medicine (Oxford), vol. 45, no. 10, pp.
597-604. https://doi.org/10.1016/j.mpmed.2017.07.011
Link to publication on Research at Birmingham portal
Publisher Rights Statement:
Shields, A. Patel, S. (2017) The primary immunodeficiency disorders, Medicine, volume 45, issue 10, pages 597-604,
https://doi.org/10.1016/j.mpmed.2017.07.011
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 13. Sep. 2019
The	primary	immunodeficiency	disorders		 	Adrian	M	Shields		Smita	Y	Patel			
Adrian M Shields MRCP PhD is an Academic Clinical Fellow in the Department of 
Clinical Immunology, Oxford University Hospitals NHS Foundation Trust, UK. 
Competing interests: none declared.		
Smita Y Patel PhD FRCPath is Consultant Immunologist at the Oxford University 
Hospitals NHS Foundation Trust and Oxford University, UK. Competing interests: 
none declared.			
Abstract	The	primary	immunodeficiency	disorders	are	clinically	heterogeneous	diseases,	most	 of	 which	 arise	 from	 inborn	 errors	 in	 immunologically	 relevant	 genes.	 A	high	 index	 of	 suspicion	 is	 required	 to	 reach	 a	 diagnosis	 of	 primary	immunodeficiency,	 and	 a	 timely	 diagnosis	 significantly	 improves	 patient	outcomes.	 This	 contribution	 reviews	 the	 relationships	 between	 the	 underlying	genetic	defects	and	the	associated	immunological	and	clinical	phenotypes	seen	in	clinical	 practice.	 Diagnostic	 and	 therapeutic	 approaches	 to	 primary	immunodeficiencies	are	also	discussed.			
Keywords	Autoimmunity;	 clinical	 immunology;	 genomics;	 infectious	 disease;	 primary	immunodeficiency		
Adrian Shields  9/6/17 15:50
C.Walker  2/6/17 19:38
Comment: We	would	prefer	to	use	“the	majority”		Numerically,	as	individual	diagnostic	entities,	the	majority	of		PIDs	arise	monogenically.			In	terms	of	prevalence,		the	most	common	PIDs	are	actually	polygenic	(e..g	CVID,	sIgA	def)	
Deleted: the	majority
	
Key	Points	
• Primary	 immune	deficiencies	present	 in	a	heterogeneous	manner,	and	a	high	 index	 of	 suspicion	 is	 required	 to	 diagnose	 primary	 immune	deficiencies.	 Any	 patient	 with	 a	 suspected	 or	 proven	 primary	immunodeficiency	 disorder	 (PID)	 should	 be	 referred	 to	 the	 care	 of	 a	clinical	immunologist	
• Depending	 on	 the	 specific	 disease,	 treatments	 for	 PIDs	 include	prophylactic	 antimicrobials,	 replacement	 immunoglobulin,	immunosuppressive	 drugs,	 bone	 marrow	 transplantation	 and	 gene	therapy	
• Genomics	approaches	have	revolutionized	the	diagnosis	of	poorly	defined	PID,	 offering	 patients	 the	 advantages	 of	 precise	 molecular	 diagnoses,	genetic	counselling	and	targeted	immunotherapeutics	
Introduction	The	immune	system	is	a	complex	network	of	cells	and	molecules	responsible	for	preserving	 tissue	 homeostasis	 by	 providing	 defence	 against	 pathogens,	performing	 tumour	 immunosurveillance	 and	 maintaining	 immunological	tolerance.	 The	 primary	 immunodeficiency	 disorders	 (PIDs)	 are	 clinically	heterogeneous	 disorders,	 most	 of	 which	 arise	 from	 genetic	 defects	 in	immunologically	relevant	genes.			PIDs	were	 once	 thought	 to	 be	 exclusively	 associated	with	 recurrent	 infections.	However,	 as	 our	 understanding	 of	 the	 complexity	 of	 cellular	 and	 signalling	networks	 has	 grown,	 it	 has	 become	 increasingly	 apparent	 that	 the	 clinical	consequences	 of	 mutations	 in	 PID	 genes	 extend	 well	 beyond	 susceptibility	 to	infection	 with	 bacteria,	 viruses	 and	 opportunistic	 organisms.	 Immune	
dysregulation	 phenotypes	 of	 PID	 are	 commonplace	 and	 include	 multiorgan	autoimmunity,	malignancy	 (particularly	 haematological)	 and	 autoinflammatory	pathology	such	as	periodic	fever	syndromes.	These	pathologies	are	not	mutually	exclusive	and	are	often	seen	in	combination.	Furthermore,	different	mutations	in	the	same	gene	can	lead	to	different	PID	presentations,	depending	on	whether	the	net	effect	is	gain	of	function	or	loss	of	function	at	the	protein	level.		Most	 PIDs	 cause	 symptoms	 in	 early	 life.	 However,	 the	 heterogeneous	constellation	 of	 symptoms	 often	 results	 in	 delayed	 diagnosis,	 to	 the	 patient’s	detriment.	Adult	presentations	of	PID	tend	to	reflect	polygenic	diseases,	such	as	common	 variable	 immunodeficiency	 disorder	 (CVID),	 or	 diseases	 in	 which	environmental	 factors	 expose	 the	 underlying	 immunological	 phenotype	 (e.g.	exposure	to	endemic	mycobacteria	can	lead	to	the	MonoMAC	phenotype	of	GATA	binding	 protein	 2	 (GATA-2)	 deficiency,	 characterized	 by	 monocytopenia	 and	non-tuberculous	mycobacterial	infection).		The	 advent	 of	 next-generation	 sequencing	 (NGS)	 has	 revolutionized	 clinical	immunology	by	allowing	detailed	characterization	of	the	genetic	architecture	of	the	 immune	 system	 in	 healthy	 individuals	 and	 patients	 with	 significant	immunological	 defects	 (Figure	 1).1	 To	 date,	 >300	 distinct,	 monogenic	 primary	
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immunodeficiencies	 have	 been	 described,	 which	 are	 classified	 in	 detail	 in	 the	2015	International	Union	of	Immunological	Societies	consensus	document.2			Below	we	contextualize	how	archetypal	PIDs	arise	from	genetic	defects	affecting	the	 three	 stages	 of	 the	 immune	 response:	 (1)	 recognition	 of	 immunological	danger,	 (2)	 immunological	 response	 to	 that	 danger,	 and	 (3)	 regulation	 of	 that	response	 to	 restore	 tissue	 homeostasis	 (Figure	 2).	 For	 the	 general	 physician,	specific	knowledge	of	 individual	PIDs	 is	not	required,	but	guidance	on	when	to	suspect	 PID	 and	 which	 simple	 investigations	 help	 in	 diagnosis	 is	 provided.	Examples	 are	 used	 to	 highlight	 features	 specific	 to	 the	 perturbed	 stage	 of	 the	immune	response.			
Genetic	defects	in	pathogen	recognition	All	 immunological	 responses	 begin	 with	 the	 recognition	 of	 a	 threat	 to	 tissue	homeostasis.	Discrimination	between	 immunological	 ‘self’	 and	 ‘non-self’	 occurs	via	 the	 identification	 of	 highly	 conserved	 motifs	 called	 pathogen-associated	molecular	 patterns	 (PAMPs),	 which	 are	 recognized	 by	 genomically	 encoded	pattern	 recognition	 receptors	 (PRRs).	 A	 variety	 of	 PRRs	 contribute	 to	 the	recognition	of	viral,	bacterial	and	fungal	PAMPs,	the	largest	family	being	the	Toll-like	 receptor	 (TLRs).	 Ligation	 of	 PRRs	 by	 cognate	 PAMPs	 initiates	 signalling	cascades	that	shape	specific	immunological	responses	against	specific	pathogens.		Immunodeficiency	 can	 occur	 when	 a	 PRR,	 its	 subcellular	 localization	 or	 its	downstream	 signalling	 is	 disrupted.	 For	 example,	 Mendelian	 susceptibility	 to	herpes	simplex	virus	(HSV)	encephalitis	can	arise	from	genetic	defects	in	TLR-3,	a	 PRR	 that	 recognizes	 double-stranded	 RNA,	 a	 by-product	 of	 HSV	 viral	replication.	 Individuals	 with	 TLR-3	 defects	 suffer	 from	 recurrent,	 severe	 HSV	encephalitis	from	an	early	age.	The	endosomal	localization	of	TLR-3	is	critical	to	its	 function,	 and	 the	 polytopic	 protein	 UNC-93B	 facilitates	 TLR-3	 subcellular	localization.	Genetic	mutations	that	prevent	interaction	between	TLR-3	and	UNC-93B	produce	an	identical	clinical	phenotype	to	TLR-3	defects,	but	neither	confers	susceptibility	 to	 other	 viral	 infections.	 Such	 selectivity	 in	 the	 role	 of	 individual	proteins	 in	 the	 defence	 against	 specific	 infectious	 disease	 is	 not	 unusual:	
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compound	 heterozygous	 mutations	 in	 the	 transcription	 factor	 IRF7,	 which	controls	 type	1	 interferon	 (IFN)	 responses,	 selectively	 confers	 susceptibility	 to	severe	influenza	infection.		Other	 TLRs	 sense	 a	 variety	 of	 bacterial	 PAMPs	 including	 lipopolysaccharide	(TLR-4),	 peptidoglycan	 (TLR-2)	 and	 flagellin	 (TLR-5),	 and	 signal	 through	 the	Myddosome,	 a	 cytosolic,	 multi-protein	 complex	 that	 assembles	 following	 TLR	ligation	 and	 initiates	 inflammatory	 gene	 expression.	 Mutations	 in	 two	 critical	components	 of	 the	 Myddosome,	 MyD88	 and	 IRAK-4,	 cause	 PID	 with	 identical	clinical	features.			MyD88	and	IRAK-4	deficiencies	are	characterized	by	recurrent	invasive	bacterial	infections	 including	 meningitis,	 sepsis,	 osteomyelitis,	 deep	 abscesses	 and	 ear,	nose	and	throat	infections.	The	spectrum	of	infection	in	these	patients	is	narrow,	despite	 the	 ubiquity	 of	 the	 Myddosome;	 Streptococcus	 pneumoniae,	
Staphylococcus	 aureus	 and	 Pseudomonas	 aeruginosa	 are	 the	 most	 commonly	isolated	organisms.	 Interestingly,	patients	become	 less	 susceptible	with	age,	 as	adaptive	immune	responses	develop	against	these	organisms.		Defects	 in	 PRRs	 can	 also	 confer	 susceptibility	 to	 fungal	 infections.	 Dectin-1	senses	β-1,3-linked	and	β-1,6-linked	glucan	from	fungal	cell	walls.	A	severe	PID	involving	 both	 chronic	 mucocutaneous	 candidiasis	 and	 deep	 dermatophytosis	can	 arise	 from	mutations	 in	 the	 gene	 encoding	 CARD9,	 a	 downstream	 adapter	protein	employed	by	dectin-1	for	signalling.		
	
Genetic	defects	in	the	immunological	response	Many	 PIDs	 arise	 from	 genetic	 mutations	 that	 prevent	 effective	 immunological	responses.	These	defects	can	be	classified	 into	those	affecting	the	 innate	or	 the	adaptive	 immune	 system.	 Innate	 immunity	 refers	 to	 molecular	 and	 cellular	mechanisms	that	respond	rapidly	and	non-specifically	 to	 immunological	 threat.	The	 adaptive	 immune	 system	 is	 characterized	 by	 lymphocytes	 that	 genetically	rearrange	 their	 receptors	 (e.g.	 the	 T	 cell	 receptor	 (TCR)	 or	 immunoglobulin	molecule)	 to	 permit	 the	 recognition	 of	 a	 diverse	 array	 of	 linear	 and	
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conformational	 epitopes	 and,	 ultimately,	 the	 establishment	 of	 long-term	immunological	 memory.	 Cross-talk	 between	 the	 two	 systems	 is	 necessary	 for	comprehensive	immunological	responses.		
Innate	immune	defects	Neutrophils	are	the	most	abundant	leucocytes	and	are	rapidly	recruited	to	sites	of	 injury,	 inflammation	 and	 immunological	 threat	 to	 participate	 in	 early	responses.	 The	 consequences	 of	 a	 relative	 or	 absolute	 absence	 of	 neutrophils	(febrile	neutropenia,	 stomatitis,	 sepsis)	are	common	complications	of	 cytotoxic	chemotherapy	 but	 are	 mirrored	 in	 severe	 congenital	 neutropenia	 and	 cyclic	neutropenia,	 PIDs	 commonly	 associated	 with	 mutations	 in	 the	 neutrophil	elastase	gene.		Leucocyte	 adhesion	 molecule	 deficiency	 arises	 if	 neutrophils	 are	 unable	 to	extravasate	 to	 access	 sites	 of	 tissue	 injury,	 a	 process	mediated	 by	 interactions	between	 adhesion	molecules	 on	 leucocytes	 and	 the	 endothelium.	Mutations	 in	integrin	 molecules	 (most	 commonly	 CD18,	 the	 β2-integrin)	 impair	 leucocyte–endothelium	 interactions	 and	 neutrophil	 extravasation.	 Individuals	 with	leucocyte	adhesion	molecule	deficiency	have	a	marked	neutrophilia,	are	unable	to	 make	 pus,	 experience	 delayed	 wound	 healing	 and	 have	 recurrent	 bacterial	skin	infections.		A	 key	 role	 of	 neutrophils	 is	 the	 phagocytosis	 and	 destruction	 of	 internalized	pathogens,	a	process	dependent	on	the	generation	of	superoxide	by	the	NADPH	complex.	Chronic	granulomatous	disease	arises	 as	 a	 result	of	mutations	within	subunits	of	the	NADPH	complex.	Consequently,	superoxide	cannot	be	generated,	and	 potassium	 flux	 into	 the	 phagolysosome,	 which	 is	 necessary	 to	 activate	destructive	antimicrobial	peptides,	 is	perturbed.	The	clinical	consequences	of	a	defective	neutrophil	respiratory	burst	are	infections	and	deep-seated	abscesses,	typically	caused	by	catalase-positive	organisms	(e.g.	Staphylococcus,	Aspergillus,	
Enterobacteriaceae	and	Candida	spp.),	non-tuberculous	mycobacterial	infections,	inflammatory	granulomas	and	inflammatory	bowel	disease	that	mimics	Crohn’s	
disease.	 Prophylactic	 antifungals	 and	 antibiotics	 are	 necessary,	 and	haemopoietic	stem	cell	transplantation	(HSCT)	is	the	treatment	of	choice.		The	 innate	 immune	 system	 contains	 a	 vast	 array	 of	 effector	 molecules	performing	 antimicrobial	 activities.	 For	 example,	 the	 complement	 system	 is	 a	cascade	of	 soluble	plasma	proteins	 that	enhance	phagocytosis	by	opsonization,	inflammation	 and	membrane	 attack.	 Early	 defects	 in	 the	 complement	 cascade	(e.g.	 C1q	 deficiency)	 lead	 to	 childhood-onset	 systemic	 lupus	 erythematosus,	glomerulonephritis	 and	 a	 predisposition	 to	 severe	 invasive	 infections.	 The	cascade	converges	 to	assemble	 the	membrane	attack	complex,	comprising	C5b,	C6,	C7,	C8	and	multiple	C9	proteins.	The	complex,	when	assembled,	allows	free	diffusion	across	the	cell	wall/membrane	of	the	target.	Defects	in	the	components	of	the	terminal	complement	cascade	lead	to	recurrent	meningitis	with	Neisseria	spp.	 A	 diagnosis	 is	 made	 from	 the	 clinical	 history	 and	 confirmed	 by	demonstrating	abnormal	haemolytic	complement	activity.	Management	involves	vaccination	and	prophylactic	antibiotics.			Cytokines	 are	 small,	 soluble	 molecules	 that	 facilitate	 intercellular	communication	within	the	 immune	system;	PIDs	can	arise	 from	genetic	defects	in	 their	 signalling	 pathways.	 For	 example,	 Mendelian	 susceptibility	 to	mycobacterial	 disease	 (MSMD)	 confers	 profound	 susceptibility	 to	 weakly	virulent,	non-tuberculous	mycobacteria	(NTM)	and	arises	from	genetic	defects	in	T	 helper	 type	 1	 cell	 (Th1)	 cytokine	 axes	 (i.e.	 IFN-γ,	 interleukin	 (IL)-12,	 IL-23).	Mycobacterial	infections	are	usually	controlled	by	complex	interactions	between	phagocytes	and	lymphocytes.	Th1	cytokines,	produced	by	Th1-polarized	CD4+	T	lymphocytes	are	 instrumental	 in	enhancing	antimycobacterial	activity	and	cell-mediated	 immunity.	 Genetic	 defects	 causing	 MSDM	 can	 arise	 at	 the	 level	 of	cytokine	receptors	(e.g.	IFN-γ	receptors	1	and	2,	common	p40	subunit	of	the	IL-12	and	 IL-23	receptor,	 IL-12	receptor	chain	β1)	or	 their	downstream	signalling	molecules	(e.g.	STAT1).3		
Adaptive	immune	defects	
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Severe	combined	 immunodeficiency	(SCID)	represents	 the	most	severe	 form	of	PID,	 and	 the	 underlying	 genetic	 defects	 typically	 prohibit	 early	 lymphocyte	development.4	The	specific	genetic	defect	determines	the	presence	or	absence	of	the	different	lymphocyte	lineages	(T	lymphocytes,	B	lymphocytes,	natural	killer	(NK)	cells)	and	consequent	immune	phenotype	of	SCID.		Autosomal	recessive	mutations	in	the	ADA	gene	allow	the	toxic	accumulation	of	deoxyadenosine	 triphosphate	 and	 S-adenosylhomocysteine	 in	 developing	lymphocytes,	leading	to	apoptosis	and	a	complete	absence	of	T,	B	and	NK	cells.	A	more	 selective	 defect	 is	 seen	 in	 X-linked	 SCID	 owing	 to	 mutations	 in	 CD132,	which	 codes	 for	 the	 common	 γ	 chain,	 which	 forms	 part	 of	 the	 receptors	 for	multiple	cytokines	including	IL-2,	IL-7	and	IL-15.	These	cytokines	are	critical	for	early	 T	 and	 NK	 cell	 development,	 but	 not	 for	 B	 cells.	 Defects	 in	 signalling	molecules	downstream	of	 the	TCR	 (e.g.	ZAP70)	and	specific	defects	 in	 the	 IL-7	pathway	 (IL-7RA)	 can	 lead	 to	 failure	 of	 T	 lymphocyte	 development	 and	 SCID	despite	the	presence	of	B	and	NK	cells.			Regardless	 of	 the	 genetic	 defect,	 the	 clinical	 presentation	 is	 similar:	 invasive	bacterial,	 viral	 and	 opportunistic	 infections,	 a	 failure	 to	 clear	 live	 vaccines,	chronic	enteropathy	and	failure	to	thrive	develop	within	the	first	months	of	life.	Early	 diagnosis	 is	 critical	 to	 good	 clinical	 outcome.	 The	 treatment	 of	 choice	 is	HSCT,	 but	 cell-based	 gene	 therapies,	 in	which	 autologous	CD34+	haemopoietic	stem	 cells	 are	 transduced	 using	 integrative	 viral	 vectors	 expressing	 functional	copies	of	the	defective	gene,	have	been	successfully	used	to	treat	X-linked	SCID	and	adenosine	deaminase	(ADA)	SCID.		Humoral	immune	deficiencies	are	much	more	common	and	are	characterized	by	a	 failure	 to	 produce	 effective	 B	 lymphocyte	 and	 immunoglobulin	 responses	 to	pathogens.	This	can	arise	from	a	primary	defect	in	B	lymphocytes.	For	example,	X-linked	 agammaglobulinaemia	 (XLA)	 arises	 from	 mutations	 in	 the	 Bruton’s	tyrosine	kinase	(BTK)	gene.	BTK	is	essential	for	B	cell	receptor	signalling	and	B	lymphocyte	 survival;	 loss	 of	 function	 leads	 to	 a	 complete	 absence	 of	 B	
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lymphocytes	 and	 immunoglobulins.	 Patients	 suffer	 from	 recurrent	 severe	sinopulmonary	infections	and	require	life-long	immunoglobulin	replacement.			The	 ability	 of	 B	 lymphocytes	 to	 class-switch	 their	 immunoglobulin	 molecules	from	the	pentameric,	low-affinity	IgM	subclass	to	higher	affinity	IgA,	IgG	and	IgE	subclasses	is	essential	in	development	of	mucosal	immunity	and	immunological	memory.	Affinity	maturation	and	class	switching	in	B	lymphocytes	is	dependent	on	T-lymphocyte	help,	specifically	the	interaction	between	CD40	and	CD40L	on	the	 surface	 of	 B	 and	 T	 lymphocytes,	 respectively.	 Genetic	 defects	 in	 CD40L	 or	CD40	cause	hyper-IgM	syndrome	types	1	and	2,	respectively,	PIDs	characterized	by	an	excess	of	 IgM,	 recurrent	bacterial	 infections	and	autoimmune	cytopenias	presenting	in	early	childhood.		CVID	 is	 the	most	 prevalent,	 clinically	 significant	PID	 and	 is	 defined	by	marked	hypogammaglobulinaemia	(IgG	<4.5	g/litre	and	reduced	concentrations	of	either	IgA	 or	 IgM),	 and	 absent	 responses	 to	 antigen	 challenge	 (e.g.	 vaccination)	 in	patients	 aged	 >4	 years.	 The	 genetic	 architecture	 of	 CVID	 is	 incompletely	understood	 but	 most	 likely	 reflects	 a	 polygenic	 disease	 with	 rare	 variants	 in	immunologically	 relevant	 genes,	 including	 TACI	 and	 BAFFR,	 conferring	susceptibility	 but	 not	 monogenic	 heritability	 for	 CVID.1	 The	 heterogeneous	clinical	presentation	of	CVID	reflects	this	genetic	architecture.			Patients	 with	 CVID	 typically	 present	 in	 early	 adulthood	 with	 recurrent	sinopulmonary	 infections.	 Some	 patients’	 disease	 does	 not	 evolve	 beyond	 this	but,	 for	 reasons	 that	 remain	 unclear,	 others	 develop	 autoimmune	 cytopenias,	increased	 risk	 of	 gastric	 and	 haematological	 malignancies,	 lymphocytic	infiltrative	diseases	and	granulomas.	A	diagnosis	of	CVID	 is	made	by	excluding	other	immune	deficiencies	according	to	European	Society	for	Immunodeficiences	(ESID)	 registry	 guidelines.	 Treatment	 targets	 the	 prevention	 of	 infectious,	autoimmune	 and	 structural	 complications	 and	 can	 include	 antibiotic	prophylaxis,	replacement	immunoglobulin	and	immunosuppression.		
Genetic	defects	in	immunological	regulation	
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Multiple	 layers	 of	 immune	 regulation	 exist	 to	 prevent	 autoimmunity	 and	 re-establish	 homeostasis	 following	 an	 immunological	 response.	 Interruption	 of	these	 regulatory	 processes	 can	 lead	 to	 PIDs	 characterized	 by	 immune	dysregulation	and/or	autoimmunity.		Central	 immunological	 tolerance	 forms	 the	 first	 layer	 of	 immunological	regulation.	 During	 T	 lymphocyte	 development,	 progenitor	 cells	 are	 subject	 to	complex	selection	processes	within	the	thymus	designed	to	minimize	the	risk	of	naive	 T	 lymphocytes	 aberrantly	 recognizing	 self-peptide	 in	 the	 context	 of	 the	major	 histocompatibility	 complex.	 The	 transcription	 factor	 autoimmune	regulator	 (AIRE)	 deliberately	 drives	 the	 expression	 of	 multiple,	 tissue-specific	self-antigens	within	the	thymus	to	negatively	selective	potentially	autoreactive	T	lymphocytes.			Autoimmune	 polyendocrinopathy	 syndrome	 type	 1	 (APS-1),	 an	 autosomal	recessive,	systemic	autoimmune	disease,	arises	from	mutations	in	the	AIRE	gene.	In	APS-1,	negative	selection	of	autoreactive	T	lymphocytes	fails;	these	cells	enter	the	 peripheral	 lymphocyte	 repertoire	 and	 cause	 multiple	 organ-specific	autoimmune	 diseases	 (e.g.	 type	 1	 diabetes	 mellitus,	 hypoparathyroidism,	hypoadrenalism,	 vitiligo).	 APS-1	 patients	 can	 also	 suffer	 from	 chronic	mucocutaneous	candidiasis	because	of	a	failure	to	establish	central	tolerance	to	IL-17,	 a	 critical	 cytokine	 in	 antifungal	 defence;	 autoimmunity	 against	 IL-17	develops	and	neutralizing	autoantibodies	inhibit	its	normal	function.		Regulatory	T	 lymphocytes	 (Tregs)	help	suppress	 immunological	 responses	and	maintain	peripheral	immunological	tolerance	using	a	variety	of	mechanisms.	The	transcription	 factor	 forkhead	 box	 P3	 (FOXP3)	 is	 critical	 for	 the	 phenotypic	stability	 of	 thymically	 derived	 Tregs.	 The	 rare	 PID	 immunodysregulation	polyendocrinopathy	 enteropathy	 X-linked	 (IPEX)	 syndrome	 is	 caused	 by	mutations	in	the	FOXP3	gene.	Infants	born	with	IPEX	present	in	the	first	month	of	life	with	 the	 triad	 of	 type	 1	 diabetes	mellitus,	 severe	 eczema	 and	 enteropathy	refractory	 to	 parenteral	 nutrition,	 and	 develop	 further	 autoimmune	complications.	 Immunologically,	 their	 Treg	 cells	 are	 unable	 to	 control	 the	
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expansion	 and	 differentiation	 of	 T	 lymphocytes,	 which	 skew	 towards	autoimmune	and	allergic	phenotypes.	HSCT	is	the	treatment	of	choice.			PID	 can	 also	 arise	 if	 the	 molecular	 mechanisms	 that	 Tregs	 use	 to	 control	inflammation	 are	 disrupted.	 CTLA-4	 is	 an	 immunoregulatory	 cell	 surface	receptor	 that	 competes	 for,	 blocks	 and	 transendocytoses	 co-stimulatory	molecules	 from	 the	 surface	 of	 antigen-presenting	 cells.	 Signals	 from	 co-stimulatory	molecules	are	necessary	for	full	T	lymphocyte	activation,	and	CTLA-4	 acts	 as	 a	 checkpoint	 against	 inappropriately	 excessive	 immunological	responses.	 Inborn	 haploinsufficiency	 of	 CTLA-4	 is	 variably	 penetrant	 but	 can	cause	 multiorgan	 lymphocytic	 infiltrates,	 hypogammaglobulinaemia,	enteropathy	and	autoimmune	cytopenias.	The	subcellular	 trafficking	of	CTLA-4	from	 the	 cell	 surface,	 through	 the	 endolysosome	 and	 back	 to	 the	 surface	 is	critical	to	its	function.	Mutations	in	LRBA,	a	large	cytosolic	protein	that	facilitates	CTLA-4	 traffic,	 produces	 an	 overlapping	 phenotype	 as	 CTLA-4	 deficiency.	Abatacept,	a	CTLA-4–Ig	molecule,	shows	remarkable	efficacy	in	both	conditions.		During	 immunological	 responses,	 lymphocytes	 with	 a	 cognate	 receptor	 for	 a	pathogen-derived	 epitope	 can	 expand	 a	 thousand-fold.	 Some	 lymphocytes	survive	 to	 form	 immunological	 memory,	 but	 most	 are	 destined	 to	 die	 by	apoptosis;	 contraction	 of	 clonal	 populations	 of	 lymphocytes	 is	 necessary	 to	restore	homeostasis.	The	Fas–Fas	 ligand	axis	plays	a	 critical	 role	 in	controlling	clonal	 lymphocyte	 contraction.	 Defects	 in	 Fas,	 Fas	 ligand	 or	 caspase	 enzymes	(caspase	 8	 and	 10)	 that	 associate	with	 the	 Fas	 receptor	 and	 engage	 apoptotic	pathways	can	 lead	to	autoimmune	lymphoproliferative	syndrome	(ALPS).	ALPS	is	 characterized	 by	 widespread	 lymphadenopathy,	 cytopenias,	 splenomegaly,	autoimmunity	 and	 an	 increased	 risk	 of	 lymphoma.	 Patients	 require	immunosuppression	and	often	HSCT.	
	
Recognizing,	diagnosing	and	treating	primary	immunodeficiency	The	 clinically	 heterogeneous	 presentations	 of	 PID	 can	 make	 them	 challenging	diagnoses	to	make,	and	it	is	essential	that	all	patients	in	whom	PID	is	suspected	are	 promptly	 referred	 to	 a	 clinical	 immunologist.	 Timely	 investigation	 and	diagnosis	 are	 essential	 to	 allow	 early	 supportive	 interventions	 (prophylactic	antimicrobials,	 avoidance	 of	 live	 vaccines,	 immunoglobulin	 replacement),	particularly	 in	 infants,	 in	 whom	 fitness	 for	 curative	 HSCT	 determines	 clinical	outcome.	A	growing	body	of	evidence	supports	the	cost-effectiveness	of	newborn	screening	 for	 SCID	 using	 molecular	 analysis	 of	 lymphocytes	 from	 dried	 blood	spot	 cards.	 However,	 these	 protocols	 are	 not	 yet	 widespread	 in	 the	 UK	 and	currently	only	test	for	severe	T	lymphocyte	defects.			A	 comprehensive	 clinical	 history	 of	 infections	 (including	 site,	 duration,	responsible	microorganism	and	response	to	treatment)	is	essential	in	evaluating	potential	PIDs.	Particular	attention	must	be	paid	 to	an	 individual’s	 response	 to	vaccinations	 and	 any	 features	 of	 PID	 or	 autoimmunity	 in	 their	 family	 history.	Table	1	summarises	the	clinical	 features	that	should	raise	suspicion	of	PID	and	merit	urgent	referral	to	an	immunology	service.			Investigating	immunodeficiencies	is	complex.	Simple	investigations	including	full	blood	count,	renal	and	 liver	profiles,	serum	immunoglobulins,	complement	and	analysis	of	lymphocyte	subsets	will	reveal	most	common	PIDs.	Secondary	causes	such	 as	 lymphoproliferative	 disease,	 retroviral	 infection	 and	 iatrogenic	 causes	should	be	excluded.	The	ESID	has	produced	a	comprehensive,	patient-centered	diagnostic	 protocol	 for	 non-immunologists	 investigating	 PID.5	 Figure	 3	illustrates	some	of	the	more	specialist	tests	used	in	the	diagnosis	of	PIDs.			The	treatment	of	immunodeficiencies	depends	on	the	type,	severity	and	clinical	manifestations.	 The	 most	 common	 immunodeficiency,	 specific	 IgA	 deficiency,	which	 affects	 1	 in	 700	 individuals,	 is	 usually	 asymptomatic,	 tends	 to	 be	 found	incidentally	 and	 requires	 no	 treatment.	However,	most	 immunodeficiencies	 do	require	treatment.			
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With	 respect	 to	 infections,	 prophylactic	 antimicrobials	 (antibiotics,	 antifungals,	occasionally	 antivirals)	 are	 used	 to	 prevent	 infections,	 and	 the	 choice	 of	 agent	should	be	guided	by	previous	microbiological	sensitivities.	Aggressive	treatment	of	 breakthrough	 infection	 is	 necessary,	 often	 with	 prolonged	 courses	 of	antimicrobials.	 When	 antimicrobials	 alone	 cannot	 prevent	 infections,	immunoglobulin	replacement	therapy	can	be	initiated	in	patients	with	antibody	deficiency	 or	 dysfunction.	 Immunoglobulin	 can	 be	 delivered	 intravenously	 or	subcutaneously,	depending	on	co-morbidities	and	patient	preference.	ADA	SCID	can	be	partially	treated	with	replacement	ADA	enzyme	injections,	restoring	the	function	of	the	defective	enzyme.		HSCT	 remains	 the	 definitive	 treatment	 for	 all	 types	 of	 SCID	 and	 the	 preferred	treatment	 option	 for	 many	 monogenic	 PIDs	 that	 present	 in	 childhood.	 The	decision	 to	 undertake	 HSCT	 is	 influenced	 by	 multiple	 factors,	 not	 least	 the	recipient’s	 overall	 condition,	 their	 ability	 to	 tolerate	 myeloablative	chemotherapeutic	 conditioning	 regimens	 and	 the	 availability	 of	 a	 haplotype-matched	 donor.	 Cell-based	 gene	 therapy	 remains	 in	 its	 infancy,	 but	 data	 from	paediatric	 patients	 with	 SCID	 and	 chronic	 granulomatous	 disease	 show	 great	promise.	In	the	context	of	PID,	the	greatest	advantage	of	gene	therapy	is	that	an	autologous	 stem	 cell	 transplant	 can	 be	 performed	 with	 gene-modified	haemopoietic	stem	cells,	removing	the	requirement	for	a	matched	donor	and	the	risk	of	graft	rejection	and	graft-versus-host	disease.			An	 emerging	 field	 in	 PID	 is	 the	 management	 of	 complications	 of	 immune	dysregulation.	 Immunosuppressive	 drugs	 are	 frequently	 required	 to	 treat	complications	 of	 CVID	 such	 as	 lymphocytic	 infiltrative	 pneumonia,	granulomatous	disease	and	autoimmune	cytopenias.	A	delicate	balance	must	be	struck	between	the	risks	and	benefits	of	 immunosuppression	 in	patients	prone	to	infection	who	also	have	immune	dysregulation.		Special	 mention	 should	 be	 made	 of	 the	 role	 of	 genomics	 in	 PID.1	 The	 rapid	reduction	 in	 cost	 and	 the	 speed	 at	which	 genomics	 investigations	 can	 now	 be	performed	 has	 revolutionized	 PID	 diagnostics	 and	 approaches	 to	 treatment.	
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Whole-exome	and	whole-genome	sequencing	have	yielded	molecular	diagnoses	in	 patients	 who	 previously	 had	 unclassified	 immune	 deficiencies,	 allowing	informed	 genetic	 counselling	 for	 affected	 families	 and	 directing	 therapeutic	management.	 Moreover,	 novel	 immune	 deficiencies	 defined	 by	 genomic	techniques	have	improved	our	understanding	of	basic	immunology,	affording	the	opportunity	 to	 use	 rational	 therapeutics	 directly	 targeted	 at	 the	 underlying	immunological	defect	(e.g.	abatacept	for	CTLA-4	and	LRBA	mutations).	
	
	
	
FIGURES	
Figure	1	The	Genomic	Architecture	of	the	Immune	System	
Figure	 2	 Archetypal	 primary	 immunodeficiencies	 in	 the	 context	 of	 the	
classical	immune	response	
Figure	3	Laboratory	investigations	in	primary	immunodeficiencies	
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TEST YOURSELF 
To test your knowledge based on the article you have just read, please complete the 
questions below. The answers can be found at the end of the issue or online here. 
 
Question 1 
An 18-year-old man presented with a 2-day history of severe headache, fever, vomiting and 
meningism. At 2 years of age, he had been admitted to paediatric intensive care with septic 
shock, but a causative organism was not identified. His sister had died of meningitis at the 
age of 5 years. 
 
On clinical examination, temperature was 38.5°C, heart rate 110 beats/minute and blood 
pressure 128/78 mmHg. A stiff neck was detected. 
 
Investigations 
 Cerebrospinal fluid: 
•Total protein 3.6 g/litre (0.15–0.45) 
•Glucose 1.1 mmol/litre (3.3–4.4) 
•Neutrophils 100/microlitre (0) 
•Gram staining showed Gram-negative cocci 
 
Analysis of serum showed normal concentrations of IgG, IgM and IgA. 
 
What is the most likely diagnosis?  
A. Encephalitis secondary to a TLR-3 deficiency 
B. X-linked agammaglobulinaemia 
C. Terminal complement deficiency 
D.  Chronic granulomatous disease. 
E.  Specific IgA deficiency  
 
Correct answer: C. The patient is likely to have a terminal complement deficiency, evidenced 
by recurrent meningococcal meningitis (Neisseria meningitidis is a Gram-negative coccus). 
There is no clinical evidence of encephalitis, and the cerebrospinal fluid is neutrophilic.The 
patient’s sister also died of meningitis, making an X-linked inheritance pattern unlikely, 
effectively excluding the XLA and the most common genetic cause of chronic granulomatous 
disease. Specific IgA deficiency is effectively excluded by normal immunoglobulin 
concentrations. 
 
 
 
Question 2 
A 3-month-old girl presented with a 1-week history of increasing shortness of breath. She also 
had a 2-week history of diarrhoea. She had been  previously admitted to hospital at 1 month 
of age with respiratory syncytial virus bronchiolitis.  She was given her first set of vaccinations 
(UK schedule) and had two healthy siblings. On examination, she was in severe respiratory 
failure and was immediately  intubated and ventilated.  
 
Investigations 
•Pneumocystis jirovecii was isolated from bronchial washings 
•Immunological investigations showed complete absence of T lymphocytes, B lymphocytes 
and natural killer cells 
 
What is the most likely diagnosis? 
A. X-linked SCID secondary to a defect in the common γ-chain (CD132)  
B. ZAP-70 SCID 
C. ADA SCID 
D. Common variable immunodeficiency disorder 
E. Chronic granulomatous disease 
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Correct answer: C. This girl has a severe combined immunodeficiency (SCID), evidenced by 
her recurrent hospital admission with both viral and fungal infections. Her diarrhoea is most 
likely to represent a viral enteropathy after being given live vaccination with rotavirus at 2 
months of age. Defects in the common γ-chain lead to X-linked SCID, which is unlikely in a 
girl. The absent T, B and natural killer cells point to adenosine deaminase  deficiency, which 
is inherited in an autosomal recessive manner, as the cause of this presentation.ZAP-70 
deficiency gives a T- B+ NK+ pattern. Chronic granulomatous disease is most commonly X-
linked and presents with deep-seated abscesses, typically caused by catalase-positive 
organisms. 
. 
 
Question 3 
A 24-year-old man was referred to the immunology clinic  with a 7-year history of chronic 
rhinosinusitis that had failed to improve after multiple sinus washouts. He had had two 
admissions to hospital in the previous 5 years with lobar pneumonia. On clinical examination, 
there were coarse bibasal crackles and splenomegaly.  
 
Investigations 
•Normal numbers of T and B-lymphocytes but has hypogammaglobulinaemia (low IgG and 
IgA but normal IgM) and does not respond to pneumococcal polysaccharide vaccination. 
Sputum culture – Haemophilus influenza (resistant to amoxicillin, sensitive to co-amoxiclav, 
macrolides and tetracyclines) 
 
What is the definitive long-term treatment? 
 
A Prophylactic penicillin V 
B Regular booster immunizations with pneumococcal conjugate vaccine 
C Gene therapy 
D Intravenous immunoglobulin replacement therapy 
E Inhaled corticosteroids 
 
Correct answer: D The likely underlying primary immunodeficiency in this case is common 
variable immune deficiency disorder. The patient should be offered immunoglobulin 
replacement therapy with the aim of raising the IgG into the normal range, reducing the 
burden of infection and arresting the progress of structural lung disease. Prophylactic 
antibiotics may be helpful, but prophylactic penicillin V is an inappropriate choice in a patient 
with amoxicillin resistant Haemophilus influenzae. Booster immunizations with pneumococcal 
conjugate vaccine are unlikely to radically alter the disease course and as common variable 
immunodeficiency is polygenic, it is not amenable to current gene therapy protocols. 
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Figure 1. The genomic architecture of the immune system. Thousands of common coding 
and non-coding genomic variants exist that have minor effects on an individual’s immune 
phenotype. At the opposite end of the spectrum, there are a handful of truly monogenic PIDs 
with 100% penetrance (e.g. CD132  mutations causing severe combined immunodeficiency 
disorder (SCID)). Between these extremes exist rare variants with significant effects on PID 
development (e.g. TACI C104R in CVID), variants that appear to lead to monogenic PID 
without 100% penetrance (e.g. CTLA4 mutations) and PID without well-defined susceptibility 
genes (e.g. Specific IgA deficiency). 
 
Figure 2. Archetypal primary immunodeficiencies in the context of the classical immune 
response. Classical immunological responses involve the recognition of immunological threat, 
a response to that threat followed by the resolution of inflammation and restoration of 
immunological and tissue homeostasis. Over 300 monogenic primary immune deficiencies 
have now been described. The clinical presentation of individual immune deficiencies is 
frequently attributable to how the underlying genetic defect disrupts these processes. APC, 
antigen-presenting cell; LoF, loss of function; MHC, major histocompatibility complex. For 
other abbreviations, see text. 
 
Figure 3. Laboratory investigations in primary immunodeficiencies. Simple haematological 
and biochemical investigations are usually sufficient to reveal most primary 
immunodeficiencies. Specialist immunological investigations may be targeted at cellular or 
molecular components of the immune system, based on clinical suspicion. Suspected single 
gene defects may be confirmed by Sanger sequencing and genomics approaches are 
undertaken only when all other avenues of investigation have failed to yield a diagnosis. 
CGD, chronic granulomatous disease; CMC, chronic mucocutaneous candidiasis; DHR, 
dihydrorhodamine; HAE, hereditary angioedema. TREC, T cell receptor excision circle. 
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lymphocytes	
Mul'ple	disease	associa'ons:	e.g.	
absent	B	lymphocytes	in	XLA,	absent	T	
lymphocytes	in	SCID,	increased	CD4–	
CD8–		T	cells	in	ALPS		
Prolifera4ve	func4on	
In	vitro	tests	measure	lymphocyte	
prolifera'on	to	non-speciﬁc	
(mitogen)	and	speciﬁc	s'muli	
(an'gen)	to	look	for	speciﬁc	defects	
Immunoglobulin	levels	
Hypogammaglobulinaemia	is	
associated	with	many	PIDs	and	confers	
suscep'bility	to	infec'on.	Hyper	IgM,	
hyper	IgE	and	hyper	IgD	syndromes	
may	also	be	diagnosed	based	on	
eleva'ons	of	their	respec've	
immunoglobulins	
Pathogen-speciﬁc	an4bodies	
An'bodies	to	speciﬁc	pathogens	may	be	
assessed	before	and	a`er	vaccina'on	to	
assess	B	lymphocyte	func'on	
An4cytokine	an4bodies	
Rare	PIDs	are	associated	with	the	
presence	of	an'bodies	against	
cytokines	(e.g.	an'-IL-17	in	CMC,	
an'-IFN-γ	in	certain	mycobacterial	
infec'ons)	
C3,	C4	levels	
Normal	in	terminal	complement	
cascade	defects.	An	isolated	low	
C4	is	associated	with	HAE	
Haemoly4c	complement	
ac4vity	(CH50,	AH50)	
In	vitro	assays	examining	the	
classical	and	alterna've	
complement	cascades.	Both	CH50	
and	AH50	are	absent	in	terminal	
complement	defects	
Quan4ﬁca4on	of	individual	
components	of	complement	
cascade	
Radial	immunodiﬀusion	assays	can	
detect	deﬁciencies	in	individual	
complement	proteins	
G
en
e7
cs
	 Sanger	sequencing	and	genomics	inves4ga4ons	
A	diagnosis	of	suspected	immunodeﬁciency	may	be	conﬁrmed	by	Sanger	sequencing	a	target	gene	to	conﬁrm	a	muta'on.	If,	a`er	exhaus've	immunological	
inves'ga'ons,	a	speciﬁc	diagnosis	can	not	be	reached,	genomic	techniques	including	whole-exome	sequencing	and	whole-genome	sequencing	may	be	employed.			
Thymic	output	
Molecular	analysis	of	TRECs	is	
helpful	in	deﬁning	thymic	func'on	
(absent	in	SCID)	
